KEYNOTE-042最終解析:ファーストラインPD-L1陽性局所進行/転移NSCLCにおけるペムブロリズマズvs化学療法
Kubota Kaoru, G. Lopes, Dang Thi Thanh Thao, Penrod Justina, M Kowalski Dariusz, K Laktionov Konstantin, Iveta Kudaba(Riga East University Hospital), DE Castro Gilberto, Z Turna Hande, Vichien Srimuninnimit(Siriraj Hospital), S K Mok Tony, C Cho Byoung, Bogusława Karaszewska(State University of Applied Sciences in Konin), Lina Yin(University of California, Los Angeles), Bondarenko Igor, Yi-Long Wu, Christian Caglevic
日本臨床腫瘍学会学術集会(CD-ROM)
January 1, 2019
Cited by 0
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k